ConductScience.org, home
Diseases
API referenceFor AI assistants

Disease · MONDO_0005578

arthritic joint disease

6 sourcesdiseases-2026-09-18-0.1.0

Download JSON
Cite this record

ConductScience Library. arthritic joint disease. Diseases, record MONDO_0005578. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005578

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name
arthritic joint disease
Open Targets
Open Targets ID
MONDO_0005578
Open Targets
Other names
Joint inflammation, arthritides, arthritis, inflammation of skeletal joint, skeletal joint inflammation
Open Targets
Disease Ontology
DOID:848
Disease Ontology
MeSH
D001168
MeSH
NCI Thesaurus
C2883
NCI Thesaurus
Highest stage of its drugs
Approval, for 35 of its 77 drugs, from DailyMed, EMA Human Drugs and TTD
Open Targets

Drugs77

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

DrugChEMBL IDTypeOpen Targets' stageStage reported byReportsOf them trialsTrials shown hereSource
METHOTREXATECHEMBL34259Small moleculeApprovalEMA Human Drugs544Drugs and targets
MENTHOLCHEMBL256087Small moleculeApprovalDailyMed2411Drugs and targets
LIDOCAINECHEMBL79Small moleculeApprovalDailyMed711Drugs and targets
NAPROXENCHEMBL154Small moleculeApprovalDailyMed610Drugs and targets
ETANERCEPTCHEMBL1201572ProteinApprovalTTD411Drugs and targets
IBUPROFENCHEMBL521Small moleculeApprovalDailyMed410Drugs and targets
ADALIMUMABCHEMBL1201580AntibodyApprovalDailyMed and EMA Human Drugs311Drugs and targets
METHYL SALICYLATECHEMBL108545Small moleculeApprovalDailyMed1400Drugs and targets
ACETAMINOPHENCHEMBL112Small moleculeApprovalDailyMed1000Drugs and targets
CAPSAICINCHEMBL294199Small moleculeApprovalDailyMed800Drugs and targets

1 to 10 of 77

See all 77 drugs

Targets147

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

TargetProteinIts drugs that act on itMechanismsHighest stage of those drugsGene in GenesSource
PTGS2Cyclooxygenase9Cyclooxygenase inhibitor; Cyclooxygenase-2 inhibitorApprovalhttps://conductscience.org/library/genes/5743Drugs and targets
PTGS1Cyclooxygenase7Cyclooxygenase inhibitorApprovalhttps://conductscience.org/library/genes/5742Drugs and targets
NR3C1Glucocorticoid receptor5Glucocorticoid receptor agonistApprovalhttps://conductscience.org/library/genes/2908Drugs and targets
JAK1Janus Kinase (JAK)3Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitorPhase 2https://conductscience.org/library/genes/3716Drugs and targets
ATP4APotassium-transporting ATPase2Potassium-transporting ATPase inhibitorApprovalhttps://conductscience.org/library/genes/495Drugs and targets
ATP4BPotassium-transporting ATPase2Potassium-transporting ATPase inhibitorApprovalhttps://conductscience.org/library/genes/496Drugs and targets
DHFRDihydrofolate reductase2Dihydrofolate reductase inhibitorApprovalhttps://conductscience.org/library/genes/1719Drugs and targets
JAK2Janus Kinase (JAK)2Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitorPhase 2https://conductscience.org/library/genes/3717Drugs and targets
MAPK14Mitogen-activated protein kinase 142MAP kinase p38 alpha inhibitorPhase 1https://conductscience.org/library/genes/1432Drugs and targets
TNFTumor necrosis factor2TNF-alpha inhibitorApprovalhttps://conductscience.org/library/genes/7124Drugs and targets

1 to 10 of 147

See all 147 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

TrialTitlePhaseParticipantsResults first postedConditionsDrugsLinked bySource
NCT00357903Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical TrialsPhase 36392010-12-06Rheumatoid ArthritisETANERCEPTIts record names the diseaseClinicalTrials.gov
NCT02728752Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy)Phase 3952021-04-21DermatomyositisHUMAN IMMUNOGLOBULIN GIts record names the diseaseClinicalTrials.gov
NCT00107783Long-Term Study of Nitisinone to Treat AlkaptonuriaPhase 2402011-01-19AlkaptonuriaNITISINONEIts record names the diseaseClinicalTrials.gov
NCT04611347Is Topical CBD Effective in Treating Thumb Joint ArthritisPhase 2182025-07-03CBD, Hand OsteoarthritisCANNABIDIOLIts record names the diseaseClinicalTrials.gov
NCT06907121Investigation of Growth Hormone and Platelet-Rich Plasma on Joint HealthPhase 2/3192Arthritis Ankle, Arthritis KneeSOMATROPINIts record names the diseaseClinicalTrials.gov
NCT04483466Methotrexate Treatment of Arthritis Caused by Chikungunya Virus (MARCH)Phase 3150Investigate the Effect(s) of Methotrexate Treatment on Arthritis Disease SeverityMETHOTREXATEIts record names the diseaseClinicalTrials.gov
NCT00542022Efficacy, Tolerability and Safety Study in Rheumatoid Arthritis (0812-008)Phase 2149Arthritis, RheumatoidMK-0812Its record names the diseaseClinicalTrials.gov
NCT02967302NEUROIMPA - Intraarticular Application of Opioids in Chronic Arthritis of the Knee JointPhase 2/3112Knee ArthritisMORPHINE, TRIAMCINOLONEIts record names the diseaseClinicalTrials.gov
NCT02749123Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and ArthritisNot applicable100Back Pain, Arthritis(+)-MENTHOL, LIDOCAINE, MENTHOLIts record names the diseaseClinicalTrials.gov
NCT06359665Oral Curcumin for the Treatment of Pain of Thumb Base Joint (CMC) ArthritisPhase 1100Arthritis of Carpometacarpal Joint of Left Thumb, Arthritis of Carpometacarpal Joint of Right ThumbCURCUMINIts record names the diseaseClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials12

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

ComparisonGroup 1, with the outcomeGroup 2, with the outcomeParticipantsTrialSource
Adult Participants vs Pediatric Participants: Serious Infectious Event114 of 5818 of 58639NCT00357903Trial comparisons
Adult Participants vs Pediatric Participants: Lymphoma6 of 5810 of 58639NCT00357903Trial comparisons
Adult Participants vs Pediatric Participants: Death23 of 5810 of 58639NCT00357903Trial comparisons
Adult Participants vs Pediatric Participants: Malignancy48 of 5810 of 58639NCT00357903Trial comparisons
Total Adults vs Pediatric Subjects: serious adverse events293 of 58116 of 58639NCT00357903Trial comparisons
Overall Period Octagam vs First Period Placebo: deaths from any cause0 of 950 of 48143NCT02728752Trial comparisons
Overall Period Octagam vs First Period Placebo: serious adverse events14 of 952 of 48143NCT02728752Trial comparisons
Octagam10% vs Placebo: Measure the Number of Patients Who Had an Increase of ≥20 Points on the Total Improvement Score (TIS)37 of 4721 of 4895NCT02728752Trial comparisons
Nitisinone-treated vs Control: serious adverse events6 of 200 of 2040NCT00107783Trial comparisons
CBD Group vs Shea Butter Group: Rate of Side Effects Using Novel CBD Cream.0 of 180 of 1836NCT04611347Trial comparisons

1 to 10 of 12

See all 12 comparisons in its trials

Papers from its trials9

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMIDListed asTrials listing itSource
40616720DERIVED1PubMed
40233998DERIVED1PubMed
39918968DERIVED1PubMed
38233885DERIVED1PubMed
37799613DERIVED1PubMed
36198179DERIVED1PubMed
36096534DERIVED1PubMed
33429735DERIVED1PubMed
20957659DERIVED1PubMed

Data dates

The date of each source this release read.

Open Targets
2026-09-18
Open Targets
Drug links and their checks, from Drugs and targets
2026-09-18
Drugs and targets
ClinicalTrials.gov, from Trials
2026-11-12
Trials
Comparisons, from Trial comparisons
2026-03-23
Trial comparisons
PubMed, for the checks
2026-11-06
PubMed
MeSH, for the checks
2026-11-10
MeSH

Sources 6

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • NLM's MeSHNLM's terms
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • NLM's MeSHNLM's
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005578

GET https://conductscience.org/api/diseases/v1/MONDO_0005578/drugs?page=2

API referenceFor AI assistants